Tarsus CCO Aziz Mottiwala departing July 15 to become CEO of another public med device company

Tarsus Pharmaceuticals, Inc.

Aziz Mottiwala to leave role as Chief Commercial Officer and employment on July 15, 2026.
Mottiwala is departing to become CEO of a public medical device company.
No successor or interim CCO has been announced by Tarsus Pharmaceuticals.
Announcement made on July 13, 2026; departure is voluntary for an external CEO opportunity.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Aziz Mottiwala

Chief Commercial Officer

TARS · Tarsus Pharmaceuticals, Inc.

Effective: 2026-07-15
Filed: July 13, 2026, 4:11 PM ET

On July 13, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Aziz Mottiwala would be leaving his role as the Company’s Chief Commercial Officer and leaving his employment with the Company on July 15, 2026, to pursue a new opportunity as Chief Executive Officer of a public medical device company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Aziz Mottiwala resigned as Chief Commercial Officer at Tarsus Pharmaceuticals, Inc..

Action: resigned
Role: Chief Commercial Officer

Exact text from the filing

On July 13, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Aziz Mottiwala would be leaving his role as the Company’s Chief Commercial Officer and leaving his employment with the Company on July 15, 2026, to pursue a new opportunity as Chief Executive Officer of a public medical device company.

View on SEC.gov

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001819790-26-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.